Imagine a world where illness is optional.

Our goal is to digitize, decode, and decipher human biology to prevent, treat, and cure chronic diseases and cancer.

In order to enhance our understanding of the origin and progression of diseases, we use a systems biology approach combined with mRNA analysis and our state-of-the-art artificial intelligence platform.

The Five Pillars of
Viome Life Sciences

Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases through a deeper understanding of an individual’s biology at a molecular level. We focus on five key initiatives:


Our direct-to-consumer service analyzes gene expressions (mRNA) in order to provide individuals with health insights and precision nutrition to live a healthier life.

This platform of ~300,000 samples enables us to enhance our understanding of human biology as a system in order to develop predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases.


Based on the longitudinal data from our testing services, we are able to develop biomarkers for most chronic diseases, cancers, and aging. With every test we are able to see an individual’s progression towards or away from identified disease biomarkers.


Our predictive biomarkers provide us with the hypothesis to do clinical research and identify the signatures of chronic diseases, cancers, and aging.


This approach, based on the use of a companion diagnostic, would ensure the selection of patients with the highest chance of having a positive response to treatment. This approach could also help to identify incremental therapeutic measures aiming at the restoration of responsiveness to therapy.


The signatures found through diagnostics allow us to determine the mechanism of action to develop precision therapeutics in the form of drugs and vaccines.

Viome can determine drug effectiveness, including immunotherapy, which is dependent upon the gut microbiome.

Our Mission

The dominant medical-healthcare industrial paradigm is rewarded for the management of the symptoms of chronic diseases, and not for prevention or cures. We are challenging this paradigm and have successfully developed over 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer, which represent over 50% of chronic diseases.

We have >20 Clinical studies in process on the road to developing diagnostics and interventions for these diseases. Recently, Viome’s AI platform has been designated a Breakthrough Device by The Food and Drug Administration (FDA) for early detection of oral cancer and throat cancer.


Our Focus Areas

We have currently discovered early molecular signatures for several diseases and biological states of interest. This includes multiple cancer types including oral and throat cancers, colorectal cancers, skin and breast cancers. It also includes chronic diseases such as Type 2 Diabetes, IBS, IBD, Depression/MDD, Anxiety, Obesity, Hashimoto’s disease, OsteoArthritis, and Acne.

Our Studies

Each of these early discoveries is a starting point for rigorous clinical studies at Viome. Once we discover biomarkers using our platform, we launch clinical studies, typically with partners in our network, to validate these hypotheses using clinical gold standards.

Active Studies


Viome Life Sciences In the News

Join us!

Our team is dedicated to making the advancements in science, technology, and medicine accessible and more readily available to all in order to create a disease-free world where people can take control of their own health. Join us on our mission to make illness optional!

Open Positions